Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 3/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508762 | 1.00 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL508769 | 0.91 | MAPK13 (0.50) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL508768 | 0.91 | MAPK13 (0.50) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL509598 | 0.85 | MAPK13 (0.48) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL508789 | 0.82 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL13363657 | 0.82 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL508061 | 0.77 | MAPT (0.51) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL508060 | 0.77 | MAPT (0.51) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL10151623 | 0.75 | TRPM8 (0.46) | MAPTTRPM8MEN1KMT2ANPC1 | |
| SCHEMBL508843 | 0.74 | MAPK13 (0.40) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010054107-A2 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054107-A2 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | MAP3K20, MAP3K6, MAP3K19 | MAPK13 130/4885MAPK12 286/4885MAPK11 284/4885 |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | MAP3K20, MAP3K6, MAP3K19 | MAPK13 130/4885MAPK12 286/4885MAPK11 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.